自治医科大学附属さいたま医療センター眼科 教授

蕪城 俊克 かぶらき としかつ 先生

公開日
2022/07/13

日本眼科学会 眼科専門医・評議員 日本眼炎症学会 理事 日本ベーチェット病学会 評議員

来歴等

略歴

1992年 東京大学 医学部 卒業
1993年 武蔵野赤十字病院 眼科 医員
1995年 東京大学附属病院 眼科 助手
2001年 東京大学大学院医学系研究科 修了 医学博士取得
2001年 東京大学附属病院 眼科 助手
2007年 東京大学附属病院 眼科 講師
2016年 東京大学附属病院 眼科 准教授
2019年 自治医科大学さいたま医療センター 眼科 教授

論文

  • 1. Combined intravitreal methotrexate and immunochemotherapy followed by reduced-dose whole-brain radiotherapy for newly diagnosed B-cell primary intraocular lymphoma. Br J Haematol. 2017;179(2):246-255

    Kaburaki T, Taoka K, Matsuda J, Yamashita H, Matsuda I, Tsuji H, Tanaka R, Nakazaki K, Nakamura F, Kamiya K, Kurokawa M, Ohtomo K, Aihara M.

  • 2. Clinical features and outcomes of secondary intraocular lymphoma. Br J Haematol. 2018;183(4):668-671

    Karakawa A, Taoka K, Kaburaki T, Tanaka R, Shinozaki-Ushiku A, Hayashi H, Miyagi-Maeshima A, Nishimura Y, Uekusa T, Kojima Y, Fukayama M, Kurokawa M, Aihara M.

  • 3. More accurate diagnosis of vitreoretinal lymphoma using a combination of diagnostic test results: a prospective observational study. Ocul Immunol Inflam. 2021, in press.

    Tanaka R, Kaburaki T, Taoka K, Karakawa A, Tsuji H, Nishikawa M, Yatomi Y, Shinozaki-Ushiku A, Ushiku T, Araki F.

  • 4. Lymphocyte proliferation induced by high-affinity peptides for HLA-B*51:01 in Behçet's uveitis.PLoS One. 2019 Sep 12;14(9):e0222384

    Kaburaki T, Nakahara H, Tanaka R, Okinaga K, Kawashima H, Hamasaki Y, Rungrotmongkol T, Hannongbua S, Noguchi H, Aihara M, Takeuchi F.

  • 5. Plasma and whole-blood chemokine levels in patients with Behçet's disease. Graefes Arch Clin Exp Ophthalmol. 2003;241(5):353-358

    Kaburaki T, Fujino Y, Kawashima H, Merino G, Numaga J, Chen J, Matsushima K.

  • 6. Initial trabeculectomy with mitomycin C in eyes with uveitic glaucoma with inactive uveitis. Eye 2009;23(7):1509-1517

    Kaburaki T, Koshino T, Kawashima H, Numaga J, Tomidokoro A, Shirato S, Araie M.

  • 7. Genetic Association of HLA-A*2601 with Ocular Behçet's Disease in Japanese Patients. Clin Exp Rheumatol. 2010;28(Suppl.60):S39-S44

    Kaburaki T, Takamoto M, Numaga J, Kawashima H, Araie M, Ohnogi Y, Harihara S, Kuwata S, Takeuchi F.

  • 8. Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behçet's disease. Graefes Arch Clin Exp Ophthalmol. 2010;248:709-714

    Kaburaki T, Araki F, Takamoto M, Okinaga K, Yoshida A, Numaga J, Fujino Y, Kawashima H.

  • 9. Retinal vascular inflammatory and occlusive changes in infectious and non-infectious uveitis. Jpn J Ophthalmol.2020 ;64(2):150-159. doi: 10.1007/s10384-020-00717-4.

    Kaburaki T, Fukunaga H, Tanaka R, Nakahara H, Kawashima H, Shirahama S, Izawa H, Komae K, Takamoto M, Soga H, Aihara M.

  • 10. Effects of Japanese herbal medicine Sairei-to on murine experimental autoimmune uveitis. Graefes Arch Clin Exp Ophthalmol. 2013;251(12):2733-2739

    Kaburaki T, Zhang Q, Jin X, Uchiyama M, Fujino Y, Nakahara H, Takamoto M, Ohtomo K, Niimi M.

  • 11. Behçet Disease Research Group of Japan. Behçet's disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. Jpn J Ophthalmol. 2014;58(2):120-130

    Kaburaki T, Namba K, Sonoda KH, Kezuka T, Keino H, Fukuhara T, Kamoi K, Nakai K, Mizuki N, Ohguro N; Ocular

  • 12. Endogenous Candida albicans infection causing subretinal abscess. Int Ophthalmol. 2010;30:203-206

    Kaburaki T, Takamoto M, Araki F, Fujino Y, Nagahara M, Kawashima H, Numaga J.

  • 13. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III. Ophthalmology. 2018;125(7):1075-108

    Suhler EB, Adán A, Brézin AP, Fortin E, Goto H, Jaffe GJ, Kaburaki T, Kramer M, Lim LL, Muccioli C, Nguyen QD, Van Calster J, Cimino L, Kron M, Song AP, Liu J, Pathai S, Camez A, Schlaen A, van Velthoven MEJ, Vitale AT, Zierhut M, Tari S, Dick AD.

  • 14. Long-Term Safety and Efficacy of Adalimumab in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. Ophthalmology. 2021;128(6):899-909

    Suhler EB, Jaffe GJ, Fortin E, Lim LL, Merrill PT, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Van Calster J, Cimino L, Adan A, Goto H, Kaburaki T, Kramer M, Vitale AT, Kron M, Song AP, Liu J, Pathai S, Douglas KM, Schlaen A, Muccioli C, Van Velthoven MEJ, Zierhut M, Rosenbaum JT.

  • 15. Incidence of sympathetic ophthalmia after inciting events: a national database study in Japan.Ophthalmology. 2022;129(3):344-352.

    Hashimoto Y, Matsui H, Michihata N, Ishimaru M, Yasunaga H, Aihara M, Kaburaki T.

  • 16. Analysis of inflammatory mediators in the vitreous humor of eyes with pan-uveitis according to aetiological classification. Sci Rep. 2020 Feb 17;10(1):2783.

    Fukunaga H, Kaburaki T, Shirahama S, Tanaka R, Murata H, Sato T, Takeuchi M, Tozawa H, Urade Y, Katsura M, Kobayashi M, Wada Y, Soga H, Kawashima H, Kohro T, Aihara M.

  • 17. Association between subfoveal choroidal thickness and leakage site on fluorescein angiography in Behçet's uveitis. Sci Rep. 2019 Jun 13;9(1):8612.

    Shirahama S, Kaburaki T, Nakahara H, Tanaka R, Komae K, Fujino Y, Kawashima H, Aihara M.

  • 18. The Relationship between Fluorescein Angiography Leakage after Infliximab Therapy and Relapse of Ocular Inflammatory Attacks in Ocular Behçet's Disease Patients.Ocul Immunol Inflamm. 2020;28(8):1166-1170.

    Shirahama S, Kaburaki T, Matsuda J, Tanaka R, Nakahara H, Komae K, Kawashima H, Aihara M.

  • 19. Comparison of visual field defect progression in secondary Glaucoma due to anterior uveitis caused by three types of herpes viruses. Graefes Arch Clin Exp Ophthalmol. 258(3),639-645, 2020. doi: 10.1007/s00417-019-04559-w.

    Shirahama S, Kaburaki T, Takada S, Nakahara H, Tanaka R, Komae K, Fujino Y, Kawashima H, Aihara M.

  • 20. Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients.Ophthalmol Ther. 2022 Mar 19.

    Namba K, Kaburaki T, Tsuruga H, Ogawa Y, Iwashita E, Goto H.

特許

  • 1. 単純ヘルペスウイルス増殖阻害剤(国立大学法人東京大学/2021年3月23日/ PCT/JP2021/011849)

本ページにおける情報は、医師本人の申告に基づいて掲載しております。内容については弊社においても可能な限り配慮しておりますが、最新の情報については公開情報等をご確認いただき、またご自身でお問い合わせいただきますようお願いします。

なお、弊社はいかなる場合にも、掲載された情報の誤り、不正確等にもとづく損害に対して責任を負わないものとします。